イプセンは2025年の予測を高め 免疫検査を買収し 新たに承認を得ました Ipsen boosts 2025 forecast, acquires ImCheck for leukemia drug, and gains new approvals.

Ipsenは,腫瘍学,まれな疾患,神経科学の優れた業績により,恒常の為替レートで2025年9月までの12.1%の収益成長を報告し,まれな疾患の売上高は97%増加しました. Ipsen reported 12.1% revenue growth through September 2025 at constant exchange rates, driven by strong performance across oncology, rare disease, and neuroscience, with rare disease sales up 97%. 同社は,全年度の売上成長予測を10%程度に上げ,約35%のコア操作余白を予測した. The company raised its full-year sales growth forecast to around 10% and projected a core operating margin of about 35%. 2025年10月22日,イプセンは,急性骨髄性白血病の試験における第一級抗体であるICT01にアクセスできるように,フランスのバイオテク企業ImCheck Therapeuticsを買収する3億5000万ユーロの現金取引を発表しました. On October 22, 2025, Ipsen announced a €350 million cash deal to acquire French biotech ImCheck Therapeutics, gaining access to ICT01, a first-in-class antibody in trials for acute myeloid leukemia. 同社はまた,IPN10200で陽性のフェーズIIの結果を共有し,日本・ヨーロッパのBolvaysとBabomeyyxの新たな規制承認を受けた. The company also shared positive Phase II results for IPN10200, and received new regulatory approvals for Bylvay® in Japan and Cabometyx® in Europe.